The team lead by Sílvia Vilares Conde, from CEDOC-NOVA Medical School, in collaboration with the pharmaceutical company Galvani Bioelectronics, demonstrated through findings in rats that is possible to restore insulin sensitivity and glucose homeostasis, by modulating electrically the carotid sinus nerve, the sensitive nerve that connects the carotid body with the brain.
The study is published in Diabetologia, the journal of the European Association for the Study of Diabetes [EASD].
In 2013, Silvia Vilares Conde and her research group described that the carotid body, a paired organ that is located in the bifurcation of the common carotid artery and that is classically defined as an oxygen sensor, regulates peripheral insulin sensitivity and that its dysfunction is involved in the development of metabolic diseases.
This first study and others afterwards performed by her group in diabetic rats showed that the bilateral resection of the carotid sinus nerve, and therefore the abolishment of the connection between the carotid body and the brain, restore insulin sensitivity and glucose tolerance. Although efficient this surgical irreversible approach has disadvantages, since the carotid body possess other physiological functions as the response to the lack of oxygen (hypoxia) or the adaptation to exercise. Silvia Conde’s team also described that the carotid body is over-activated in animal models of type 2 diabetes, suggesting that decreasing the activity of the organ could be a good therapeutic strategy.
From the partnership with Galvani Bioelectronics (former Glaxo Smith Kline Bioelectronics), the opportunity to electrically modulate the carotid sinus nerve come up. In fact, this work demonstrated that is possible to maintain glucose homeostasis in animals in which electrodes have been implanted in the carotid sinus nerve and submitted to electrical modulation, without significant adverse effects. It has also been demonstrated that the electrical modulation is reversible. Silvia Conde notes that “this work opens the door to the development of a new therapeutic for type 2 diabetes that will provide a long-term management of the disease with negligible adverse effects and interference with daily activities”.
Type 2 diabetes is characterized by insulin resistance and by increased hepatic glucose production that culminates in hyperglycemia. Although a lot of efforts have been performed until the date none therapeutic induce long-term glycaemia control, being expected for the next decades a huge increase in the prevalence of the disease. Thus, this work gives hope to patients with metabolic diseases, as it brings a new approach for the management of type 2 diabetes.
The Latest on: Type 2 diabetes
UAB diabetes researchers: Old drug could provide new promise for diabetes patients
on July 11, 2018 at 3:44 pm
In 2014, Shalev found that verapamil reversed the effects of Type 1 diabetes and the human trials began after the CDC received a $2.1 million grant from the JDRF, a research fund focused on diabetes r... […]
Your doctor says you have type 2 diabetes. What next?
on July 11, 2018 at 3:38 pm
A little over 1 million Australians have been diagnosed with type 2 diabetes. Another half a million are believed to have it — but don't know it. And another 2 million have prediabetes, meaning they'r... […]
New study links walnuts to lower risk of Type 2 diabetes
on July 11, 2018 at 2:51 pm
A new epidemiological study representing more than 34,000 American adults suggests that those who consume walnuts may have about half the risk of developing type 2 diabetes compared to adults who do n... […]
People with type 2 diabetes more likely to suffer from breathlessness, restrictive lung disease
on July 11, 2018 at 10:53 am
Breathlessness and conditions of restrictive lung disease (RLD), such as pulmonary fibrosis, may be a late complication of type 2 diabetes. These are the key findings of a joint study undertaken by re... […]
High prevalence of restrictive lung disease in people with type 2 diabetes
on July 11, 2018 at 10:51 am
Breathlessness and conditions of restrictive lung disease (RLD), such as pulmonary fibrosis, may be a late complication of type 2 diabetes. Breathlessness and conditions of restrictive lung disease (R... […]
Type 2 diabetes—is it what you eat, or how much?
on July 11, 2018 at 5:22 am
Type 2 diabetes is a growing concern. Already, two million Australians and almost half a billion people worldwide have diabetes. At least one in three adults will develop diabetes as they age, costing ... […]
Researchers may have found new a way to help treat type 1 diabetes – and it's with a drug that has been on the market for over 30 years
on July 11, 2018 at 12:16 am
There are two types of diabetes, type 2 diabetes, in which the body becomes insulin resistant and can't effectively use it, and type 1 diabetes, in which the immune system destroys large portions of t... […]
Type 1 Diabetes in Mothers Linked to Higher Risk of Autism in Children
on July 10, 2018 at 2:48 pm
Researchers say they found that women who have type 1 diabetes during pregnancy were at a greater risk of having offspring with autism than even mothers with type 2 diabetes or gestational diabetes. “ ... […]
UTRGV med school awarded NIH grant for type 2 diabetes research
on July 10, 2018 at 12:08 pm
UTRGV med school awarded NIH grant for type 2 diabetes research By Jennifer L. Berghom, Special to the Star Valley Morning Star Dr. Sara M. Reyna, assistant professor in the Department of Biomedical S... […]
Standard type 2 diabetes treatments may not improve the condition in youth
on July 10, 2018 at 7:49 am
Taking insulin or the most commonly used drug for type 2 diabetes, metformin, failed to either delay or effectively treat the condition in youth, according to a study led by a Yale researcher. In the ... […]
via Google News and Bing News